For the Inventor, By the Inventor

Enter inventor name

Seattle, WA, United States of America

Kerry W Fowler

USPTO Granted Patents = 45 (Patent Applications = 9)

CIPO Patents = 3 (Patent Applications = 4)

EPO Patents = 4 (Patent Applications = 8)

Average Co-Inventor Count = 3.6

ph-index = 14

Forward Citations = 638(Granted Patents)

Location History:

Chicago, IL (US) (1986 - 1992)
Seattle, WA (US) (1991 - 2024)

Company Filing History:

Icos Corporation

G.d. Searle & Company

4. 2 out of 769

Indiana University

Deltagen Research Labs, LLC

Oculon Corporation

where one patent can have more than one assignee

Years Active: 1986-2024

Loading Chart...

Loading Chart...

Loading Chart...

45 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 11858889 - Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease (2024-01-02),

2. 11267780 - Compound for modulating DDAH and ADMA levels, as well as methods of using thereof to treat disease (2022-03-08),

3. 10906907 - Tert-butyl (s)-(1-(5-fluoro-4-oxo-3-phenyl-3,4-dihydroquinazolin-2-yl)propyl)carbamate precursor of a quinazolinone inhibitor of human phosphatidylinositol 3-kinase delta and a process for preparing thereof (2021-02-02),

4. 10336756 - (S)-2-(1-aminopropyl)-5-fluoro-3-phenylquinazolin-4(3H)-one precursor of a quinazolinone as inhibitor of human phosphatidylinositol 3-kinase delta (2019-07-02),

5. 9956285 - Anti-viral compounds (2018-05-01),

6. 9884876 - Anti-viral compounds, pharmaceutical compositions, and methods of use thereof (2018-02-06),

7. 9555106 - Anti-viral compounds (2017-01-31),

8. 9149477 - 5-fluoro-3-phenyl-2-[1-(9h-purin-6-ylamino)propyl]-3h-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta (2015-10-06),

9. 9073946 - Anti-viral compounds (2015-07-07),

10. 8993583 - 5-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta (2015-03-31),

11. 8980901 - 5-fluoro-3-phenyl-2[1-(9H-purin-6-ylamino)propyl]-3H-quinazolin-4-one and 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as inhibitors of human phosphatidylinositol 3-kinase delta (2015-03-17),

12. 8779131 - 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)-ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta (2014-07-15),

13. RE44638 - Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta (2013-12-09),

14. 8586597 - 6-fluoro-3-phenyl-2-[1-(9H-purin-6-ylamino)ethyl]-3H-quinazolin-4-one as an inhibitor of human phosphatidylinositol 3-kinase delta (2013-11-19),

15. RE44599 - Quinazolinones as inhibitors of human phosphatidylinositol 3-kinase delta (2013-11-11),

Title: Unveiling the Innovations of Inventor Kerry W Fowler

Introduction: Kerry W Fowler, a prolific inventor based in Seattle, WA, has made significant contributions to the field of pharmaceuticals and healthcare through his groundbreaking patents.

Latest Patents: Among Kerry W Fowler's impressive portfolio of 45 patents, his recent work on a compound for modulating DDAH and ADMA levels stands out. These compounds play a crucial role in treating and preventing diseases associated with imbalanced levels of DDAH and ADMA. The pharmaceutical compositions developed by Fowler have the potential to revolutionize disease management strategies.

Career Highlights: Kerry W Fowler has honed his expertise while working at reputable companies such as Icos Corporation and G.D. Searle & Company. His innovative approach to research and development has led to the creation of novel solutions in the healthcare industry, solidifying his reputation as a distinguished inventor.

Collaborations: Throughout his career, Kerry W Fowler has collaborated with esteemed professionals in the field, including coworkers like Amy Oliver and Edward A Kesicki. These collaborations have not only enriched his work but have also paved the way for interdisciplinary breakthroughs in the realm of pharmaceutical innovation.

Conclusion: In conclusion, Kerry W Fowler's relentless pursuit of innovation and his invaluable contributions to the field of healthcare underscore his status as a trailblazing inventor. His patented compounds and pharmaceutical compositions serve as a testament to his dedication to advancing medical science and improving global health outcomes.

This text is generated by artificial intelligence and may not be accurate.

Please report any incorrect information to support@idiyas.com

Loading…